Document is current

Article History

Received: 29 April 2025

Revised: 9 June 2025

Accepted: 9 July 2025

First Online: 9 August 2025

Declarations

:

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Kyoto University Graduate School of Medicine and the Japanese Red Cross Wakayama Medical Center and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: According to our institutional review board guidelines, informed consent was not required for the retrospective review of patient medical records.

: None of the authors has any proprietary interest in any product described in this article. The authors wish to report the following relationships: M. Hata: Novartis Pharma, Senju Pharmaceutical, Alcon Research Institute, and Kyoto Drug Discovery and Development; A. N. Ueda-Arakawa: Santen Pharmaceutical, Novartis Pharma, and Chugai Pharmaceutical; H. Tamura: Findex, Bayer Yakuhin, Novartis Pharma, Santen Pharmaceutical, SUNTORY, and Otsuka Pharmaceutical; M Miyata: Alcon Japan, Novartis Pharma, Santen Pharmaceutical, HOYA, Bayer Yakuhin, Senju Pharmaceutical, and Kowa Pharmaceutical; A. Tsujikawa: Canon, Findex, Santen Pharmaceutical, Kowa Pharmaceutical, Pfizer, AMO Japan, Senju Pharmaceutical, Wakamoto Pharmaceutical, Alcon Japan, Alcon Pharma, Otsuka Pharmaceutical, Tomey Corporation, Taiho Pharma, Hoya, Bayer Yakuhin, Novartis Pharma, Chugai Pharmaceutical, Astellas, Eisai, Daiich-Sankyo, Janssen Pharmaceutical, Kyoto Drug Discovery and Development, Allergan Japan, MSD, Ellex, HOYA, Sanwa Kagaku Kenkyusho, Nitten Pharmaceutical, and AbbVie GK.

: None.